Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients.: An EORTC-receptor and Biomarker Group collaboration

被引:26
作者
Riisbro, R
Christensen, IJ
Nielsen, HJ
Brünner, N
Nilbert, A
Fernebro, E
机构
[1] Copenhagen Univ Hosp, Finsen Lab, Copenhagen, Denmark
[2] Hvidovre Univ Hosp, Dept Surg Gastroenterol, Hvidovre, Denmark
[3] Royal Vet & Agr Univ, Inst Vet Pathobiol, Frederiksberg, Denmark
[4] Univ Hosp, Jubileum Inst, Dept Oncol, Lund, Sweden
关键词
rectal cancer; soluble urokinase plasminogen receptor; suPAR; prognosis;
D O I
10.1177/172460080502000203
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background and aims: Since approximately 30% of patients with Dukes' stage B colorectal cancer will experience disease recurrence within five years of primary treatment, current staging of patients with early colorectal cancer apparently fails to adequately predict patient outcome. It has previously been shown that the preoperative plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) is associated with the survival of patients with early colorectal cancer. In this study we sought to confirm the independent prognostic value of suPAR in rectal cancer. Methods: suPAR was retrospectively determined by two different versions of a suPAR ELISA in preoperatively collected plasma samples from a Swedish (n=354) and a Danish (n=255) cohort of rectal cancer patients. Results: In both cohorts the suPAR concentration was significantly higher in Dukes' stage D patients than in Dukes' stage A-C patients (p < 0.0001). Among Dukes' stage A-C patients, no differences in median suPAR values were seen. In univariate analysis, continuous suPAR was found to be associated with survival (p < 0.0001 in both cohorts). Of particular interest was that similar results were obtained for Dukes' stage A and B patients when analyzed separately. In multivariate analysis, continuous suPAR was found in both cohorts to be independent of Dukes' stage. Conclusions: This study confirms that the preoperative concentration of plasma suPAR contains independent prognostic information on patients with rectal cancer. This result was independent of the two different versions of an in-house suPAR ELISA used to perform the analyses. The next step. in the evaluation of suPAR as a prognostic parameter in rectal cancer will be to launch an appropriately dimensioned prospective study where the benefit of applying preoperative plasma suPAR measurement to clinical decision-making regarding adjuvant therapy is assessed.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 50 条
[41]   Elevated soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients [J].
Lippi, Giuseppe ;
Henry, Brandon M. ;
Favaloro, Emmanuel J. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (11) :E413-E415
[42]   Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy [J].
Lupusoru, Gabriela ;
Ailincai, Ioana ;
Sorohan, Bogdan Marian ;
Andronesi, Andreea ;
Achim, Camelia ;
Micu, Georgia ;
Caragheorgheopol, Andra ;
Manda, Dana ;
Lupusoru, Mircea ;
Ismail, Gener .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 182
[43]   Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD [J].
Gumus, Aziz ;
Altintas, Nejat ;
Cinarka, Halit ;
Kirbas, Aynur ;
Haziroglu, Muge ;
Karatas, Mevlut ;
Sahin, Unal .
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 :357-365
[44]   Association of plasma soluble urokinase plasminogen activator receptor concentrations and migraine with aura: a REFORM study [J].
Tesfay, Betel ;
Ashina, Hakan ;
Christensen, Rune Haeckert ;
Al-Khazali, Haidar M. ;
Karlsson, William Kristian ;
Amin, Faisal Mohammad ;
Jawad, Baker Nawfal ;
Andersen, Ove ;
Ashina, Messoud .
BRAIN COMMUNICATIONS, 2025, 7 (01)
[45]   Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor [J].
Dowsett, Joseph ;
Ferkingstad, Egil ;
Rasmussen, Line Jee Hartmann ;
Thorner, Lise Wegner ;
Magnusson, Magnus K. ;
Sugden, Karen ;
Thorleifsson, Gudmar ;
Frigge, Mike ;
Burgdorf, Kristoffer Solvsten ;
Ostrowski, Sisse Rye ;
Sorensen, Erik ;
Erikstrup, Christian ;
Pedersen, Ole Birger ;
Hansen, Thomas Folkmann ;
Banasik, Karina ;
Brunak, Soren ;
Tragante, Vinicius ;
Lund, Sigrun Helga ;
Stefansdottir, Lilja ;
Gunnarson, Bjarni ;
Poulton, Richie ;
Arseneault, Louise ;
Caspi, Avshalom ;
Moffitt, Terrie E. ;
Gudbjartsson, Daniel ;
Eugen-Olsen, Jesper ;
Stefansson, Hreinn ;
Stefansson, Kari ;
Ullum, Henrik .
COMMUNICATIONS BIOLOGY, 2021, 4 (01)
[46]   Soluble urokinase-type plasminogen activator receptor as a putative marker of male accessory gland inflammation [J].
Autilio, C. ;
Morelli, R. ;
Milardi, D. ;
Grande, G. ;
Marana, R. ;
Pontecorvi, A. ;
Zuppi, C. ;
Baroni, S. .
ANDROLOGY, 2015, 3 (06) :1054-1061
[47]   Plasma Level of Soluble Urokinase-type Plasminogen Activator Receptor Predicts the Severity of Acute Alcohol Pancreatitis [J].
Nikkola, Anssi ;
Aittoniemi, Janne ;
Huttunen, Reetta ;
Rajala, Linnea ;
Nordback, Isto ;
Sand, Juhani ;
Laukkarinen, Johanna .
PANCREAS, 2017, 46 (01) :77-82
[48]   Utilization of Prognostic Biomarker Soluble Urokinase Plasminogen Activator Receptor in the Emergency Department: A Tool for Safe and More Efficient Decision-making [J].
Holstein, Ria M. ;
Makinen, Marja T. ;
Castren, Maaret K. ;
Kaartinen, Johanna M. .
BIOMARKER INSIGHTS, 2022, 17
[49]   The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever [J].
Yilmaz, Gurdal ;
Mentese, Ahmet ;
Kaya, Selcuk ;
Uzun, Aysegul ;
Karahan, S. Caner ;
Koksal, Iftihar .
JOURNAL OF CLINICAL VIROLOGY, 2011, 50 (03) :209-211
[50]   Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia [J].
Atfy, Maha ;
Eissa, Mohamad ;
Salah, Hossam E. ;
El Shabrawy, Deena A. .
MEDICAL ONCOLOGY, 2012, 29 (03) :2063-2069